We recently sat down with Jonathan Cherry, Global Project Leader, to learn more about PTC’s ferroptosis and inflammation scientific platform and how it relates to #FriedreichAtaxia (FA). Read more: bit.ly/44KxkBa

RBC Global Healthcare Conference: PTC Therapeutics's CEO summarizes a busy year ahead of regulatory decisions and data. $PTCT

Full video: biotechtv.com/post/ptc-thera…

Today we announced that the FDA has accepted our filing of the BLA for Upstaza™, a gene therapy for the treatment of AADC deficiency. Read more: bit.ly/4bGXdEh

Our 2023 Corporate Sustainability Report is now available. It was a transformational year for PTC, but our commitment to environmental stewardship, social responsibility and corporate governance remained a key focus. Read more: bit.ly/3WCQjLU

PTC is proud to announce that we have been granted Gallup’s Don Clifton Strengths-Based Culture Award for 2024! Congratulations to all our employees for making PTC an engaging and innovative place to work. Learn more: bit.ly/3QBXuQK

Expanding insights and knowledge about #rarediseases is essential to improving patient outcomes. At the ISPOR 2024 Annual Meeting, we’ll share six poster presentations focused on the latest health economics research across four of our key therapeutic areas. #ISPORAnnual

We’re pleased to share that our 2023 annual report is now available. Read our full report for more on PTC's transformative year and how we're positioning the company for future success. bit.ly/3wmE1fY

PTC Therapeutics announced that we will present a company overview at two upcoming investor conferences. Read more: bit.ly/3y2BQP5

Today, our leaders provided a corporate update and reported our first quarter 2024 financial results. Read more: bit.ly/3xTt31Y

Are you a U.S. healthcare professional interested in learning more about our opt-in program for PKU? Visit ReimaginePKU.com to connect with our team.

Raising awareness for rare diseases empowers patients and drives progress. Learn how to advocate for yourself and others in this article! bit.ly/3RkvMcg #RareDisease #PatientAdvocacy

We applaud this important research to help advance the understanding of Friedreich ataxia and the progression of the condition in children.

We're onsite at #SIMD2024 and sticking around for #GMDI 2024 to share our #PKU updates and insights below.

Join PTC tomorrow at 4 p.m. ET for a sponsored educational symposium for #healthcare professionals attending the #SIMD2024 Annual Meeting. This symposium will review results from the Phase 3 APHENITY trial in #PKU . Learn more and register: bit.ly/43VRMym

Join PTC on April 16 for a sponsored educational symposium for #HealthCareProfessionals attending the #SIMD2024 Annual Meeting. This symposium will discuss unmet needs in #PKU and review results from the Phase 3 APHENITY trial. Learn more and register: bit.ly/43VRMym

Don't miss our presentations at #AANAM2024 for updates on our innovative therapies for rare neurological disorders.

Today, PTC announced that it will host a conference call to discuss its first quarter 2024 financial results on Thursday, April 25 at 4:30 p.m. ET. Read more: bit.ly/3vNM9G1

Today, PTC announced the submission of a marketing authorization application to the EMA for our investigational therapy for the treatment of PKU. Read more: bit.ly/3IYas7i

Angela Minnella, Director of Neuroscience at PTC, is moderating a panel discussion and speaking on the role of ferroptosis in the development and progression of neurodegenerative disease at the 6th Annual Neuroimmunology Drug Development Summit. Hope to see you there!

We recently sat down with Jeff Trimmer JTrim, Senior VP, Research Site Head, to learn more about PTC’s ferroptosis and inflammation scientific platform and the team at PTC working on this program. Read more: bit.ly/3VpTYMD